Samixogrel

Drug Profile

Samixogrel

Alternative Names: DDX 30; DTTX 30; DTTX 30SE

Latest Information Update: 22 Jul 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
  • Class Antithrombotics
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic complications; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 22 Jul 2011 Discontinued - Phase-II for Thrombosis in Germany (PO)
  • 22 Jul 2011 Discontinued - Preclinical for Diabetic complications in Spain (unspecified route)
  • 22 Jul 2011 Discontinued - Preclinical for Thrombosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top